Hannah Kim
Papers
1
Total Citations
13
H-Index
1
About
Dr. Hannah Kim is a pioneering oncologist whose research focuses on the molecular characterization and therapeutic targeting of rare gynecologic malignancies, particularly low-grade serous ovarian carcinoma (LGSOC). Her landmark 2024 study, "High-throughput drug screening identifies novel therapeutics for Low Grade Serous Ovarian Carcinoma," has already garnered 13 citations, reflecting its immediate impact on the field. By recognizing that LGSOC possesses distinct molecular features from the more common high-grade serous ovarian carcinoma—and that pivotal clinical trials often exclude these patients—Dr. Kim’s work fills a critical gap. Her high-throughput screening approach has identified promising new drug candidates, offering hope for a patient population with limited treatment options. This contribution not only advances precision oncology but also underscores her commitment to addressing underserved areas in cancer research. Dr. Kim’s dedication to translating laboratory discoveries into clinical applications positions her as a rising leader in ovarian cancer therapeutics, inspiring both students and fellow researchers to pursue innovative solutions for rare diseases.
Research Focus
Key Achievements
Top Papers
- 1